Zhengtong Lv

Zhengtong Lv

Auto-generated profile, based on publicly available information

Zhengtong Lv

Department of Urology, Xiangya Hospital, Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in HIV/AIDS - Research and Palliative Care
Verified
Journal Article
Open access
YWYong Wang
Yong Wang
ZLZhengtong Lv
Zhengtong Lv
YCYuan Chu
Yuan Chu
Highly active antiretroviral therapy (HAART) is recognized as the most effective treatment method for AIDS, and protease inhibitors play a very important role in HAART. However, poor bioavailability and unbearable toxicity are their common disadvantages. Thus, the development of safer and potentially promising protease inhibitors is eagerly needed. In this review, we introduced the chemical characteristics and associated side effects of HIV protease inhibitors, as well as the possible off-target mechanisms causing the side effects. From the chemical structures of HIV protease inhibitors and their possible off-target molecules, we could obtain hints for optimizing the molecular selectivity of the inhibitors, to provide help in the design of new compounds with enhanced bioavailability and reduced side effects.

27 February 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HJHuichuan Jiang
Huichuan Jiang
WXWei Xiong
Wei Xiong
LCLingxiao Chen
Lingxiao Chen
ZLZhengtong Lv
Zhengtong Lv
CYChangzhao Yang
Changzhao Yang
YLYuan Li
Yuan Li

3 June 2019 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
ZLZhengtong Lv
Zhengtong Lv
HJHuichuan Jiang
Huichuan Jiang
XHXiheng Hu
Xiheng Hu
CYChangzhao Yang
Changzhao Yang
HCHarripersaud Chand
Harripersaud Chand
YLYuan Li
Yuan Li

1 June 2020 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
ZLZhengtong Lv
Zhengtong Lv
YCYi Cai
Yi Cai
HJHuichuan Jiang
Huichuan Jiang
CYChangzhao Yang
Changzhao Yang
CTCongyi Tang
Congyi Tang
YLYuan Li
Yuan Li
Background: The enhanced recovery after surgery (ERAS) and fast track surgery (FTS) protocols have been applied to a variety of surgeries and have been proven to reduce complications, accelerate rehabilitation, and reduce medical costs. However, the effectiveness of these protocols in minimally invasive radical prostatectomy (miRP) is still unclear. Thus, this study aimed to evaluate the impact of ERAS and FTS protocols in miRP. Methods: We searched PubMed, Cochrane Library, Embase, and Web of Science databases to collect randomized and observational studies comparing ERAS/FTS versus conventional care in miRP up to July 1, 2019. After screening for inclusion, data extraction, and quality assessment by two independent reviewers, the meta-analysis was performed with the RevMan 5.3 and STATA 15.1 software. Results were expressed as risk ratio (RR) and weighted mean difference (WMD) with 95% confidence intervals (CIs). Results: In total, 11 studies involving 1,207 patients were included. Pooled data showed that ERAS/FTS was associated with a significant reduction in length of stay (LOS) (WMD: –2.41 days, 95% CI: –4.00 to –0.82 days, P=0.003), time to first anus exhaust (WMD: –0.74 days, 95% CI: –1.14 to –0.34 days, P=0.0003), and lower incidence of postoperative complications (RR: 0.70, 95% CI: 0.53 to 0.92, P=0.01). No significant differences were found between groups for operation time, estimated blood loss, postoperative pain, blood transfusion rate, and readmission rate (P>0.01). Conclusions: Our meta-analysis suggests that the ERAS/FTS protocol is safe and effective in miRP. However, more extensive, long-term, prospective, multicenter follow-up studies, and randomized controlled trials (RCTs) are required to validate our findings.

28 August 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
XLXingbo Long
Xingbo Long
LWLongxiang Wu
Longxiang Wu
XZXiting Zeng
Xiting Zeng
ZWZhijian Wu
Zhijian Wu
XHXiheng Hu
Xiheng Hu
YLYuan Li
Yuan Li
To evaluate whether the addition of biomarkers to traditional clinicopathological parameters may help to increase the accurate prediction of prostate re‐biopsy outcome. A training cohort with 98 patients and a validation cohort with 72 patients were retrospectively recruited into our study. Immunohistochemical analysis was used to evaluate the immunoreactivity of a group of biomarkers in the initial negative biopsy normal‐looking tissues of the training and validation cohorts. p‐STAT3, Mcm2, and/or MSR1 were selected out of 10 biomarkers to construct a biomarker index for predicting cancer and high‐grade prostate cancer (HGPCa) in the training cohort based on the stepwise logistic regression analysis; these biomarkers were then validated in the validation cohort. In the training cohort study, we found that the biomarker index was independently associated with the re‐biopsy outcomes of cancer and HGPCa. Moreover supplementing the biomarker index with traditional clinical‐pathological parameters can improve the area under the receiver operating characteristic curve of the model from 0.722 to 0.842 and from 0.735 to 0.842, respectively, for predicting cancer and HGPCa at re‐biopsy. In the decision‐making analysis, we found the model supplemented with the biomarker index can improve patients’ net benefit. The application of the model to clinical practice, at a 10% risk threshold, would reduce the number of biopsies by 34.7% while delaying the diagnosis of 7.8% cancers and would reduce the number of biopsies by 73.5% while delaying the diagnosis of 17.8% HGPCas. Taken together, supplementing the biomarker index with clinicopathological parameters may help urologists in re‐biopsy decision‐making processes.

9 June 2022 in Cancer Medicine
Verified
Journal Article
Open access
XWXuan Wang
Xuan Wang
ZLZhengtong Lv
Zhengtong Lv
HXHaoran Xia
Haoran Xia
XGXiaoxiao Guo
Xiaoxiao Guo
JWJianye Wang
Jianye Wang
MLMing Liu
Ming Liu
Prostate cancer (PCa) is a unique cancer from a metabolic perspective. Androgen receptor assumes a vital part in normal and malignant prostate cells regarding almost all aspects of cell metabolism, such as glucose, fat, amino acids, nucleotides, and so on. We used The Cancer Genome Atlas database as training set, Memorial Sloan‐Kettering Cancer Center cohort as validation set, and Gene Expression Omnibus database (GSE70769) as test set to identify the optimal prognostic signature. We evaluated the signature in terms of biochemical progression‐free survival (bPFS), ROC curve, clinicopathological features, independent prognostic indicators, tumor microenvironment, and infiltrating immune cells. Nomogram was built dependent on the results of cox regression analyses. GSEA algorithm was used to evaluate differences in metabolism. The signature's prediction of androgen deprivation therapy (ADT) response was validated based on two groups of basic cytological experiments treat with ADT (GSE143408 and GSE120343) and the transcriptional information of pre‐ADT/post‐ADT of six local PCa patients. We finally input four screened genes into the stepwise regression model to construct metabolism‐related signature. The signature shows good prediction performance in training set, verification set, and test set. A nomogram based on the PSA, Gleason score, T staging, and the signature risk score could predict 1‐, 3‐, and 5‐year bPFS with the high area under curve values. Based on gene‐set enrichment analysis, the characteristics of four genes signature could influence some important metabolic biological processes of PCa and were serendipitously found to be significantly related to androgen response. Subsequently, two cytological experimental data sets and our local patient sequencing data set verified that the signature may be helpful to evaluate the therapeutic response of PCa to ADT. Our systematic study definite a metabolism‐related gene signature to foresee prognosis of PCa patients which might add to individual prevention and treatment.